A study analysing irAEs of extended interval dosing of checkpoint inhibitors among patients during COVID-19 pandemic
Latest Information Update: 16 Jul 2021
At a glance
- Drugs Durvalumab (Primary) ; Pembrolizumab (Primary)
- Indications Cancer; Lung cancer
- Focus Adverse reactions
- 16 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology